Oral Oncology
Volume 46, Issue 9 , Pages 657-661 , September 2010

Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis

  • Tomoko Ota

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • ,
  • Kazutoshi Ota

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 96 373 5288; fax: +81 96 373 5286.
    • ,
  • Hirofumi Jono

      Affiliations

    • Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • ,
  • Hiromi Fujimori

      Affiliations

    • Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • ,
  • Mitsuharu Ueda

      Affiliations

    • Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • ,
  • Satoru Shinriki

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • ,
  • Takanao Sueyoshi

      Affiliations

    • Department of Orthopaedic and Neuro-Musculoskeletal Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • ,
  • Masanori Shinohara

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
    • ,
  • Yukio Ando

      Affiliations

    • Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan

Received 3 May 2010 ,Revised 5 June 2010 ,Accepted 7 June 2010.

References 

  1. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8(3):177–184
  2. Alves FA, Pires FR, De Almeida OP, Lopes MA, Kowalski LP. PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours. Int J Oral Maxillofac Surg. 2004;33(6):593–597
  3. Jones AV, Franklin CD. An analysis of oral and maxillofacial pathology found in adults over a 30-year period. J Oral Pathol Med. 2006;35(7):392–401
  4. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 2002;8(5):229–240
  5. Ito FA, Ito K, Vargas PA, de Almeida OP, Lopes MA. Salivary gland tumors in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg. 2005;34(5):533–536
  6. Satoh J, Muramatsu H, Moretto G, Muramatsu T, Chang HJ, Kim ST, et al. Midkine that promotes survival of fetal human neurons is produced by fetal human astrocytes in culture. Brain Res Dev Brain Res. 1993;75(2):201–205
  7. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997;57(9):1814–1819
  8. Sumi Y, Muramatsu H, Hata K, Ueda M, Muramatsu T. Midkine enhances early stages of collagen gel contraction. J Biochem. 2000;127(2):247–251
  9. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T, et al. Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem. 1999;73(5):2084–2092
  10. Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S, Muramatsu T. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem. 1997;122(2):453–458
  11. Muramatsu H, Muramatsu T. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun. 1991;177(2):652–658
  12. Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol. 2001;167(6):3463–3469
  13. Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 2004;50(5):1420–1429
  14. Yoshida Y, Goto M, Tsutsui J, Ozawa M, Sato E, Osame M, et al. Midkine is present in the early stage of cerebral infarct. Brain Res Dev Brain Res. 1995;85(1):25–30
  15. Salama RH, Muramatsu H, Shimizu E, Hashimoto K, Ohgake S, Watanabe H, et al. Increased midkine levels in sera from patients with Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(4):611–616
  16. Garver RI, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer. 1994;74(5):1584–1590
  17. Garver RI, Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol. 1993;9(5):463–466
  18. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology. 1999;57(3):253–257
  19. Ye C, Qi M, Fan QW, Ito K, Akiyama S, Kasai Y, et al. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer. 1999;79(1):179–184
  20. Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, et al. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer. 2008;99(4):655–662
  21. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 1995;55(8):1792–1797
  22. Maeda S, Shinchi H, Kurahara H, Mataki Y, Noma H, Maemura K, et al. Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer. 2007;97(3):405–411
  23. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, et al. Serum midkine depends on lymph node involvement and correlates with circulating VEGF-C in oesophageal squamous cell carcinoma. Biomarkers. 2007;12(4):403–413
  24. Ruan M, Ji T, Wu Z, Zhou J, Zhang C. Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg. 2007;36(2):159–164
  25. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8
  26. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol. 2002;22(19):6788–6796
  27. van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, et al. The growth factor midkine antagonizes VEGF signaling in vitro and in vivo. Neoplasia. 2008;10(4):340–347
  28. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T, Kadomatsu K. Midkine rescues Wilms’ tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by midkine. J Biochem. 2000;127(2):269–277
  29. Mirkin BL, Clark S, Zheng X, Chu F, White BD, Greene M, et al. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene. 2005;24(31):4965–4974
  30. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer. 2006;107(4):864–873

PII: S1368-8375(10)00187-9

doi: 10.1016/j.oraloncology.2010.06.004

Oral Oncology
Volume 46, Issue 9 , Pages 657-661 , September 2010

Article Tools

* Image Usage & Resolution